Expression of p53 and its mechanism in prostate cancer

Wan,Jiukai; Zhang,Jun; Zhang,Junqiang

doi:10.3892/ol.2018.8680

Expression of p53 and its mechanism in prostate cancer

Authors:
- Jiukai Wan
- Jun Zhang
- Junqiang Zhang
View Affiliations

Affiliations: Department of Urology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
Published online on: May 9, 2018 https://doi.org/10.3892/ol.2018.8680
Pages: 378-382
Copyright: © Wan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression of tumor protein p53 (p53), and its mechanism of function, in prostate cancer (PC). Small interfering RNA (siRNA) was used to interfere with p53 expression in the PC cell line, DU145. Cell viability and p53 expression were analyzed using cell counting kit‑8 (CCK‑8) and western blotting. The effects of p53 expression on the proliferation, migration and adhesion abilities of PC cells were analyzed using Cell Counting kit‑8, Transwell and adhesion assays. Changes in cell proliferation, migration and adhesion ability were observed following treatment with extracellular signal‑regulated kinase (ERK) inhibitor, PD184352, and janus kinase (JNK) inhibitor, SP60012. The expression level of p53 declined 24 h after siRNA transfection (P<0.05). Furthermore, JNK and ERK, downstream proteins of the focal adhesion kinase (FAK)‑Src proto‑oncogene, non‑receptor tyrosine kinase (Src) signaling pathway, were activated. These effects were associated with reduced proliferation, migration and adhesion abilities of PC cells compared with untransfected control cells (P<0.05). PD184352 and SP600125 treatments also resulted in reduced proliferation, migration and adhesion abilities of PC cells (P<0.05). In conclusion, PC cells exhibited low p53 expression, and the proliferation, migration and adhesion abilities of PC cells were promoted by inhibiting the activation of JNK and ERK. Together, these results suggest that p53 has potential as a therapeutic target in PC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Jiang T, Zhou C, Gu J, Liu Y, Zhao L, Li W, Wang G, Li Y and Cai L: Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA. Cancer Lett. 337:133–142. 2013. View Article : Google Scholar : PubMed/NCBI
3	Nande R, Greco A, Gossman MS, Lopez JP, Claudio L, Salvatore M, Brunetti A, Denvir J, Howard CM and Claudio PP: Microbubble-assisted p53, RB, and p130 gene transfer in combination with radiation therapy in prostate cancer. Curr Gene Ther. 13:163–174. 2013. View Article : Google Scholar : PubMed/NCBI
4	Wang Y, Zhang YX, Kong CZ, Zhang Z and Zhu YY: Loss of P53 facilitates invasion and metastasis of prostate cancer cells. Mol Cell Biochem. 384:121–127. 2013. View Article : Google Scholar : PubMed/NCBI
5	Sivoňová MK, Vilèková M, Kliment J, Mahmood S, Jureèeková J, Dušenková S, Waczulíková I, Slezák P and Dobrota D: Association of p53 and p21 polymorphisms with prostate cancer. Biomed Rep. 3:707–714. 2015. View Article : Google Scholar : PubMed/NCBI
6	Gu J, Wang B, Liu Y, Zhong L, Tang Y, Guo H, Jiang T, Wang L, Li Y and Cai L: Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo. Eur J Cancer. 50:1184–1194. 2014. View Article : Google Scholar : PubMed/NCBI
7	Xie Q, Lu YY and Yi HF: Expression and clinical significance of Caspase-3 and P53 in gastric cancer. Chin J Gastroenterol Hepatol. 23:1287–1289. 2014.
8	Ha US, Bae WJ, Kim SJ, Yoon BI, Hong SH, Lee JY, Hwang TK, Hwang SY, Wang Z and Kim SW: Anthocyanin induces apoptosis of DU-145 cells in vitro and inhibits xenograft growth of prostate cancer. Yonsei Med J. 56:16–23. 2015. View Article : Google Scholar : PubMed/NCBI
9	Teh BS and Ishiyama H: Hypofractionated radiotherapy for prostate cancer. Lancet Oncol. 13:5–6. 2012. View Article : Google Scholar : PubMed/NCBI
10	Henríquez-Hernández LA, Valenciano A, Foro-Arnalot P, Álvarez-Cubero MJ, Cozar JM, Suárez-Novo JF, Castells-Esteve M, Fernández-Gonzalo P, De-Paula-Carranza B, Ferrer M, et al: Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study. Urol Oncol. 33:331.e1–e7. 2015. View Article : Google Scholar
11	Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M and Stattin P: Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study. Int J Cancer. 138:2154–2160. 2016. View Article : Google Scholar : PubMed/NCBI
12	Alva A and Hussain M: Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer. Drugs. 73:1517–1524. 2013. View Article : Google Scholar : PubMed/NCBI
13	Meek DW: Regulation of the p53 response and its relationship to cancer. Biochem J. 469:325–346. 2015. View Article : Google Scholar : PubMed/NCBI
14	Singh RD, Patel KR and Patel PS: p53 mutation spectrum and its role in prognosis of oral cancer patients: A study from Gujarat, West India. Mutat Res. 783:15–26. 2016. View Article : Google Scholar : PubMed/NCBI
15	Zhang G, Li Z, Lin XM, Zhang JH, Cui Y and Zhao X: Expression and significance of PTEN, S100A4 and p53 protein in breast invasive ductal carcinoma. Guangdong Med J. 35:3510–3512. 2014.
16	Cai S and Han K: Research on expression and importance of p53, p16 and VEGF-C in cervical cancer. J Gynecol Obstet Biol Reprod (Paris). 44:639–645. 2015. View Article : Google Scholar : PubMed/NCBI
17	Thakur R, Trivedi R, Rastogi N, Singh M and Mishra DP: Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep. 5:101942015. View Article : Google Scholar : PubMed/NCBI
18	Zhang H, Zhang SH, He HW, Zhang CX, Yu DK and Shao RG: Downregulation of G3BPs inhibits the growth, migration and invasion of human lung carcinoma H1299 cells by suppressing the Src/FAK-associated signaling pathway. Cancer Gene Ther. 20:622–629. 2013. View Article : Google Scholar : PubMed/NCBI